Basak KİLİC, HÜLYA ÇİÇEK, Ayse Ozlem METE, Suleyman GANİDAGLİ, Berna Kaya UĞUR

Effects of Parenteral Glutamine Supplementation on Endocan Levels in Septic Patients

The purpose of this study was to investigate the effect of parentera l Glutamine (Gln) supplementation on Endocan levels in patients with sepsis receiving parenteral nutrition. A total of 60 patients with a diagnosis of sepsis were enrolled to the study. Patients were randomly divided into two groups to receive either standard parenteral nutrition or standard parenteral nutrition plus the parenteral dipeptide Gln-Ala. The Gln-Ala dipeptide dosage was calculated to be 0.35 mg/kg. Demographic data, CRP, ESR, lactate, WBC, Endocan serum levels, APACHE II scores at admission to ICU, and SOFA scores at day 0, 3rd and 7th days were all recorded. The outcomes of the patients were also recorded after 28-day follow up. Results: There was no statistically significant difference between the Endocan values of patients receiving parente ral dipeptide Gln-Ala plus the standard parenteral nutrition vs standard parenteral nutrition. Also, there was no significant difference in mortality and septic shock development rates between the two groups. According to our results, there was not a significant difference regarding outcomes of the patients in both study groups, including mortality rates and there was no beneficial effect of indiscriminate GLN supplementation. Further prospective studies with larger sample size are needed in order to make conclusive comments that there is no beneficial effect of administering GLN.

PDF

___

1. De Backer D. Benefit-risk assessment of drotrecogin alfa (activated) in the treat- ment of sepsis, Drug Saf 2007; 30: 995-1010.

2. Qiao R., Wang H, Yan W, L.E. et al. Extracellular matrix hyaluronan is a determinant of the endothelial barrier, Am. J. Phys. Cell Phys 1995; 269: C103-C109.

3. Scherpereel A, Depontieu F, Grigoriu B, et al. Endocan, a new endothelial marker in human sepsis. Crit Care Med 2006; 34: 532-537.

4. Coeffier M, Dechelotte P. The role of glutamine in intensive care unit patients: mechanisms of action and clinical outcome. Nutrition reviews 2005; 63: 65-69.

5. Parry-Billings M, Evans J, Calder PC, Newsholme EA Does glutamine contribute to immunosuppression after major burns? Lancet 1990; 336: 523-525.

6. Wischmeyer PE. Glutamine: mode of action in critical illness. Critical care medicine 2007; 35; 541-544.

7. Wernerman J. Role of glutamine supplementation in critically ill patients. Current opinion in anaesthesiology 2008; 21: 155-159.

8. Addabbo F, Chen Q, Patel DP, et al. Glutamine supplementation alleviates vasculopathy and corrects metabolic profile in an in vivo model of endothelial cell dysfunction. PloS one 2013; 8; e65458.

9. Vermeulen MA, Brinkmann SJ, Stehle P, van Leeuwen PA. Consequences of the REDOXS and METAPLUS Trials: the end of an era of glutamine and antioxidant supplementation for critically ill patients? JPEN J Parenter Enteral Nutr 2016; 40: 12.

10. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016; 23: 315: 801-810

11. Harris JA, Benedict FG. A Biometric Study of Human Basal Metabolism. Proc Natl Acad Sci U S A. 1918; 4: 370-373.

12. Recknagel P, Gonnert FA, Westermann M, et al. Liver dysfunction and phosphatidylinositol3-kinase signalling in early sepsis: experimental studies in rodent models of peritonitis, PLoS Med 2012; 9: e1001338.

13. Ziegler TR, Benfell K, Smith RJ, et al. Safety and metabolic effects of L-glutamine administration in humans. JPEN Journal of parenteral and enteral nutrition 1990; 14: 137- 146.

14. Roth E. Nonnutritive effects of glutamine. The Journal of nutrition 2008; 138; 2025- 2031.

15. Brunengraber H, Roe CR. Anaplerotic molecules: current and future. Journal of inherited metabolic disease 2006; 29: 327-331.

16. Owen OE, Kalhan SC, Hanson RW. The key role of anaplerosis and cataplerosis for citric acid cycle function. The Journal of biological chemistry 2002; 277: 30409-30412.

17. O’Riordan E, Mendelev N, Patschan S, et al. Chronic NOS inhibition actuates endothelial-mesenchymal transformation. American journal of physiology Heart and circulatory physiology 2007; 292: 285-294.

18. Mihajlovic DM, Lendak DF, Brkic SV, et al. Endocan is useful biomarker of survival and severity in sepsis. Microvasc Res 2014; 93: 92- 97.

19. Alberti C, Brun-Buisson C, Burchardi H, et al. Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med 2002; 28: 108-121.

20. Mihajlovic D, Brkic S, Lendak D, et al. Endothelial biomarkers in the light of new sepsis definition. Biomark Med 2019; 13: 341- 351.

21. Palmiere C, Augsburger M. Endocan measurement for the postmortem diagnosis of sepsis. Leg Med (Tokyo) 2014; 16: 1-7.

22. Wernerman J. Glutamine supplementation. Ann Intensive Care 2011; 18; 1: 25.

23. Stehle P, Ellger B, Kojic D, et al. Glutamine dipeptide-supplemented parenteral nutrition improves the clinical outcomes of critically ill patients: A systematic evaluation of randomised controlled trials. Clin Nutr ESPEN. 2017; 17; 75-85.

24. Gunst J, Vanhorebeek I, Thiessen SE, Van den Berghe G. Amino acid supplements in critically ill patients. Pharmacol Res 2018; 130: 127-131.

25. Tao KM, Li XQ, Yang LQ, et al. Glutamine supplementation for critically ill adults. Cochrane Database Syst Rev 2014; 9: CD010050.

26. Buter H, Bakker AJ, Kingma WP, Koopmans M, Boerma EC. Plasma glutamine levels in patients after non-elective or elective ICU admission: an observational study. BMC Anesthesiol. 2016; 10; 16: 15. 27. Harvey SE, Parrott F, Harrison DA, et al. Trial of the route of early nutritional support in critically ill adults. N Engl J Med 2014; 371: 1673-1684.

28. Berg A, Rooyackers O, Norberg A, Wernerman J. Elimination kinetics of Lalanyl-L-glutamine in ICU patients. Amino Acids 2005; 29: 221-228.

29. Melis GC, Boelens PG, van der Sijp JR, et al. The feeding route (enteral or parenteral) affects the plasma response of the dipeptide Ala-Gln and the amino acids glutamine, citrulline and arginine, with the administration of Ala-Gln in preoperative patients. Br J Nutr 2005; 94: 19-26.

30. van Zanten AR, Hofman Z, Heyland DK. Consequences of the REDOXS and METAPLUS Trials: the end of an era of glutamine and antioxidant supplementation for critically ill patients? JPEN J Parenter Enteral Nutr 2015; 39: 890-892.

31. Wernerman J. What Is Actually Attributable to Glutamine? JPEN J Parenter Enteral Nutr. 2017; 41: 9.

32. Wernerman J. How to understand the results of studies of glutamine supplementation. Crit Care 2015; 19: 385.

33. Buijs N, Vermeulen MA, van Leeuwen PA. Glutamine and antioxidants in critically ill patients. N Engl J Med 2013; 369: 484.

34. Vermeulen MA, Brinkmann SJ, Stehle P, van Leeuwen PA. Consequences of the REDOXS and METAPLUS Trials: the end of an era of glutamine and antioxidant supplementation for critically ill patients? JPEN J Parenter Enteral Nutr. 2016; 40: 12.

35. Buijs N, Vermeulen MA, van Leeuwen PA. Glutamine and antioxidants in critically ill patients. N Engl J Med 2013; 369: 484.

36. Heyland D, Muscedere J, Wischmeyer PE, et al. A randomized trial of glutamine and antioxidants in critically ill patients. N Engl J Med 2013; 368: 1489-1497.

37. Smedberg M, Wernerman J. Is the glutamine story over? Crit Care 2016; 10: 361.

38. Sakr Y, Jaschinski U, Wittebole X, et al. ICON Investigators. Sepsis in Intensive Care Unit Patients: Worldwide Data From the Intensive Care over Nations Audit. Open Forum Infect Dis. 2018; 19; 5; ofy313.